SNX-2112, also known as PF-04928473, is a small molecule inhibitor of heat shock protein 90 (HSP90), which is a molecular chaperone involved in the folding and stabilization of various proteins. It was first discovered in 2005 and has since been studied for its potential as a treatment for various types of cancer.
Chemical name:
The chemical name for SNX-2112 is 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylphenyl)-1,2,4-triazole-3-thiol.
Molecular formula:
The molecular formula of SNX-2112 is C25H30N6O3S.
Formula weight:
The formula weight of SNX-2112 is 498.61 g/mol.
CAS No:
The CAS number of SNX-2112 is 908112-43-6.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
SNX-2112 has been primarily developed for the treatment of cancer. It is an inhibitor of HSP90, which is a molecular chaperone involved in the folding and stabilization of various proteins, including those involved in cancer cell growth and survival. By inhibiting HSP90, SNX-2112 may induce cancer cell death and inhibit their proliferation.
Potential effects:
Some potential effects of SNX-2112 include:
Product mechanism:
SNX-2112 works by inhibiting HSP90, which is a molecular chaperone involved in the folding and stabilization of various proteins, including those involved in cancer cell growth and survival. By inhibiting HSP90, SNX-2112 can induce protein misfolding and degradation, leading to cancer cell death and inhibition of their proliferation.
Safety:
SNX-2112 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with SNX-2112.
Side effects:
SNX-2112 can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of SNX-2112 has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 10 to 100 mg/kg. In clinical trials, doses ranged from 150 to 500 mg once weekly. The drug is typically administered intravenously.
Conclusion:
SNX-2112 is a small molecule inhibitor of HSP90 that has shown potential as a treatment for various types of cancer. By inhibiting HSP90, SNX-2112 may induce cancer cell death and inhibit their proliferation. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of SNX-2112 in treating various types of cancer.
